Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of one of the following
* Newly diagnosed de novo acute myeloid leukemia (AML)
* AML secondary to myelodysplastic syndromes (MDS)
* AML secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years
Bone marrow blasts \>30%
Age ≥ 65 years
Easter Cooperative Oncology Group (ECOG) 0-2
You may not be if
Previous cytotoxic or biologic treatment for AML (except hydroxyurea)
Previous treatment with azacitidine, decitabine or cytarabine
Prior use of targeted therapy agents (e.g., FLT3 inhibitors, other kinase inhibitors)
AML French American British subtype (FAB M3)
AML associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes
Prior bone marrow or stem cell transplantation
Candidate for allogeneic bone marrow or stem cell transplant
Diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, "in-situ" carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure)
Malignant hepatic tumors
Uncontrolled systemic infection
Active viral infection with Human Immunodeficiency Virus (HIV) or Hepatitis type B or C
Use of any experimental drug or therapy within 28 days prior to Day 1
Clareo Health | Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
